- Corporate Officers - S
- Silvernail Lauren P
Insider Trading History of Silvernail Lauren P
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Silvernail Lauren P since 2005.
This trader's CIK number is 1225755.
At the time of last reporting, Silvernail Lauren P was the See Remarks of Evolus, Inc.. (stock ticker symbol EOLS).
Also see all insider trading activities at Evolus, Inc..
Note that in the past
SILVERNAIL LAUREN P also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Revance Therapeutics, Inc. (RVNC) by Silvernail Lauren P
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2018 | RVNC | 0 | $0 | 52,172 | $1,725,174 | 45,867 | $399,042 |
2017 | RVNC | 0 | $0 | 22,957 | $602,236 | 50,506 | $439,401 |
2014 | RVNC | 980 | $17,380 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Evolus, Inc. (EOLS) by Silvernail Lauren P
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2022 | EOLS | 0 | $0 | 78,396 | $970,493 | 0 | $0 |
2021 | EOLS | 0 | $0 | 16,992 | $179,915 | 0 | $0 |
2019 | EOLS | 0 | $0 | 2,612 | $35,353 | 0 | $0 |
Yearly summary of insider trading at Ista Pharmaceuticals Inc (ISTA) by Silvernail Lauren P
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2012 | ISTA | 0 | $0 | 0 | $0 | 145,813 | $740,584 |
2011 | ISTA | 2,500 | $10,725 | 0 | $0 | 62,667 | $190,695 |
2008 | ISTA | 17,000 | $10,693 | 0 | $0 | 0 | $0 |
2005 | ISTA | 5,000 | $37,635 | 0 | $0 | 0 | $0 |
Insider trading activities at 3 companies by Silvernail Lauren P:
1. Revance Therapeutics, Inc. (RVNC)
2. Evolus, Inc. (EOLS)
3. Ista Pharmaceuticals Inc (ISTA)
Table 1. Insider trading of Revance Therapeutics, Inc. (RVNC) by Silvernail Lauren P
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2018-05-22 | RVNC | Sale | 2,874 | 30.25 | 86,924 |
2018-03-22 | RVNC | Sale | 3,431 | 30.85 | 105,839 |
2018-03-13 | RVNC | Option Ex | 25,867 | 8.70 | 225,042 |
2018-03-13 | RVNC | Sale | 25,867 | 34.50 | 892,411 |
2018-03-09 | RVNC | Sale | 10,000 | 32.50 | 325,000 |
2018-03-07 | RVNC | Option Ex | 10,000 | 8.70 | 87,000 |
2018-03-07 | RVNC | Sale | 10,000 | 31.50 | 315,000 |
2018-03-09 | RVNC | Option Ex | 10,000 | 8.70 | 87,000 |
2017-12-26 | RVNC | Option Ex | 17,506 | 8.70 | 152,302 |
2017-11-07 | RVNC | Sale | 10,000 | 26.83 | 268,270 |
2017-11-07 | RVNC | Option Ex | 10,000 | 8.70 | 87,000 |
2017-10-12 | RVNC | Sale | 11,164 | 26.67 | 297,755 |
2017-05-26 | RVNC | Option Ex | 23,000 | 8.70 | 200,099 |
2017-05-22 | RVNC | Sale | 1,793 | 20.20 | 36,211 |
2014-12-11 | RVNC | Buy | 980 | 17.73 | 17,380 |
Table 2. Insider trading of Evolus, Inc. (EOLS) by Silvernail Lauren P
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2022-05-17 | EOLS | Sale | 16,189 | 13.92 | 225,350 |
2022-05-18 | EOLS | Sale | 52,015 | 12.42 | 646,026 |
2022-03-08 | EOLS | Sale | 10,192 | 9.72 | 99,117 |
2021-08-10 | EOLS | Sale | 14,293 | 11.18 | 159,781 |
2021-01-25 | EOLS | Sale | 2,699 | 7.46 | 20,134 |
2019-05-31 | EOLS | Sale | 2,612 | 13.54 | 35,353 |
Table 3. Insider trading of Ista Pharmaceuticals Inc (ISTA) by Silvernail Lauren P
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2012-05-08 | ISTA | Option Ex | 145,813 | 5.08 | 740,584 |
2011-08-11 | ISTA | Buy | 2,500 | 4.29 | 10,725 |
2011-05-10 | ISTA | Option Ex | 62,667 | 3.04 | 190,695 |
2008-12-09 | ISTA | Buy | 17,000 | .63 | 10,693 |
2005-05-12 | ISTA | Buy | 5,000 | 7.53 | 37,635 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Silvernail Lauren P
(See Remarks of Evolus, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.